Cargando…
Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer
AIM: To assess the impact of hepatitis B surface (HBsAg) seroclearance on survival outcomes in hepatitis B-related primary liver cancer. METHODS: Information from patients with hepatitis B-related liver cancer admitted in our hospital from 2008-2017 was retrieved. Cases diagnosed with HBsAg (-) and...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107526/ https://www.ncbi.nlm.nih.gov/pubmed/30148147 http://dx.doi.org/10.12998/wjcc.v6.i8.192 |
_version_ | 1783349980399927296 |
---|---|
author | Lou, Cheng Bai, Tong Bi, Le-Wei Gao, Ying-Tang Du, Zhi |
author_facet | Lou, Cheng Bai, Tong Bi, Le-Wei Gao, Ying-Tang Du, Zhi |
author_sort | Lou, Cheng |
collection | PubMed |
description | AIM: To assess the impact of hepatitis B surface (HBsAg) seroclearance on survival outcomes in hepatitis B-related primary liver cancer. METHODS: Information from patients with hepatitis B-related liver cancer admitted in our hospital from 2008-2017 was retrieved. Cases diagnosed with HBsAg (-) and HBcAb (+) liver cancer were included in the HBsAg seroclearance (SC) group. HBsAg (+) liver cancer patients strictly matched for liver cancer stage (AJCC staging system, 8(th) edition), Child-Pugh score, and first diagnosis/treatment method (surgery, ablation and TACE) were assigned to the HBsAg non-seroclearance (NSC) group. Then, clinical, pathological and survival data in both groups were assessed. RESULTS: The SC and NSC groups comprised of 72 and 216 patients, respectively. Patient age (P < 0.001) and platelet count (P = 0.001) in the SC group were significantly higher than those of the NSC group. SC group patients who underwent surgery had more intrahepatic cholangiocarcinoma (ICC) and combined HCC-CC (CHC) cases than the NSC group, but no significant differences in tumor cell differentiation and history of liver cirrhosis were found between the two groups. The numbers of interventional treatments were similar in both groups (4.57 vs 5.07, P > 0.05). Overall survival was lower in the SC group than the NSC group (P = 0.019), with 1-, 3-, and 5-year survival rates of 82.1% vs 85.1%, 43.2% vs 56.8%, and 27.0% vs 45.2%, respectively. Survival of patients with AJCC stage I disease in the SC group was lower than that of the NSC group (P = 0.029). CONCLUSION: Seroclearance in patients with hepatitis B-related primary liver cancer has protective effects with respect to tumorigenesis, cirrhosis, and portal hypertension but confers worse prognosis, which may be due to the frequent occurrence of highly malignant ICC and CHC. |
format | Online Article Text |
id | pubmed-6107526 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-61075262018-08-24 Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer Lou, Cheng Bai, Tong Bi, Le-Wei Gao, Ying-Tang Du, Zhi World J Clin Cases Case Control Study AIM: To assess the impact of hepatitis B surface (HBsAg) seroclearance on survival outcomes in hepatitis B-related primary liver cancer. METHODS: Information from patients with hepatitis B-related liver cancer admitted in our hospital from 2008-2017 was retrieved. Cases diagnosed with HBsAg (-) and HBcAb (+) liver cancer were included in the HBsAg seroclearance (SC) group. HBsAg (+) liver cancer patients strictly matched for liver cancer stage (AJCC staging system, 8(th) edition), Child-Pugh score, and first diagnosis/treatment method (surgery, ablation and TACE) were assigned to the HBsAg non-seroclearance (NSC) group. Then, clinical, pathological and survival data in both groups were assessed. RESULTS: The SC and NSC groups comprised of 72 and 216 patients, respectively. Patient age (P < 0.001) and platelet count (P = 0.001) in the SC group were significantly higher than those of the NSC group. SC group patients who underwent surgery had more intrahepatic cholangiocarcinoma (ICC) and combined HCC-CC (CHC) cases than the NSC group, but no significant differences in tumor cell differentiation and history of liver cirrhosis were found between the two groups. The numbers of interventional treatments were similar in both groups (4.57 vs 5.07, P > 0.05). Overall survival was lower in the SC group than the NSC group (P = 0.019), with 1-, 3-, and 5-year survival rates of 82.1% vs 85.1%, 43.2% vs 56.8%, and 27.0% vs 45.2%, respectively. Survival of patients with AJCC stage I disease in the SC group was lower than that of the NSC group (P = 0.029). CONCLUSION: Seroclearance in patients with hepatitis B-related primary liver cancer has protective effects with respect to tumorigenesis, cirrhosis, and portal hypertension but confers worse prognosis, which may be due to the frequent occurrence of highly malignant ICC and CHC. Baishideng Publishing Group Inc 2018-08-16 2018-08-16 /pmc/articles/PMC6107526/ /pubmed/30148147 http://dx.doi.org/10.12998/wjcc.v6.i8.192 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Case Control Study Lou, Cheng Bai, Tong Bi, Le-Wei Gao, Ying-Tang Du, Zhi Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer |
title | Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer |
title_full | Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer |
title_fullStr | Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer |
title_full_unstemmed | Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer |
title_short | Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer |
title_sort | negative impact of hepatitis b surface seroclearance on prognosis of hepatitis b-related primary liver cancer |
topic | Case Control Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107526/ https://www.ncbi.nlm.nih.gov/pubmed/30148147 http://dx.doi.org/10.12998/wjcc.v6.i8.192 |
work_keys_str_mv | AT loucheng negativeimpactofhepatitisbsurfaceseroclearanceonprognosisofhepatitisbrelatedprimarylivercancer AT baitong negativeimpactofhepatitisbsurfaceseroclearanceonprognosisofhepatitisbrelatedprimarylivercancer AT bilewei negativeimpactofhepatitisbsurfaceseroclearanceonprognosisofhepatitisbrelatedprimarylivercancer AT gaoyingtang negativeimpactofhepatitisbsurfaceseroclearanceonprognosisofhepatitisbrelatedprimarylivercancer AT duzhi negativeimpactofhepatitisbsurfaceseroclearanceonprognosisofhepatitisbrelatedprimarylivercancer |